Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Patterson

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
ACS Infectious Diseases|January 23, 2020
The Q<sub>i</sub> Site of Cytochrome <i>b</i> is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i>Richard J Wall, Sandra Carvalho, Rachel Milne, et al.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
Journal of Medicinal Chemistry|July 15, 2020
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> ActivityMichael G Thomas, Manu De Rycker, Richard J Wall, et al.
Journal of Medicinal Chemistry|June 21, 2023
Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static-Cidal Screening of AnaloguesLaura A T Cleghorn, Richard J Wall, Sébastien Albrecht, et al.
Science Translational Medicine|July 9, 2025
Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas diseaseLindsay B Tulloch, Hugh Tawell, Annie E Taylor, et al.
Journal of Medicinal Chemistry|March 18, 2022
Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal TrypanosomiasisAlasdair Smith, Richard J Wall, Stephen Patterson, et al.
Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.
Journal of Medicinal Chemistry|December 21, 2018
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral LeishmaniasisMichael G Thomas, Manu De Rycker, Myriam Ajakane, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
ACS Infectious Diseases|January 23, 2020
The Q<sub>i</sub> Site of Cytochrome <i>b</i> is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i>Richard J Wall, Sandra Carvalho, Rachel Milne, et al.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
Journal of Medicinal Chemistry|July 15, 2020
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> ActivityMichael G Thomas, Manu De Rycker, Richard J Wall, et al.
Journal of Medicinal Chemistry|June 21, 2023
Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static-Cidal Screening of AnaloguesLaura A T Cleghorn, Richard J Wall, Sébastien Albrecht, et al.
Science Translational Medicine|July 9, 2025
Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas diseaseLindsay B Tulloch, Hugh Tawell, Annie E Taylor, et al.
Journal of Medicinal Chemistry|March 18, 2022
Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal TrypanosomiasisAlasdair Smith, Richard J Wall, Stephen Patterson, et al.
Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.
Journal of Medicinal Chemistry|December 21, 2018
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral LeishmaniasisMichael G Thomas, Manu De Rycker, Myriam Ajakane, et al.
Pageof 6